Subscribe to our Newsletters !!
The life cycle of malaria is a complex process inv
METTLER TOLEDO announces the launch of four new la
Relevant codes should be used when coding fibromya
Sun Pharma, a prominent pharmaceutical enterprise
Principal Component Analysis (PCA) is a powerful t
It is important to understand that natural remedie
In a world constantly in motion, Microbioz India r
New Delhi, Oct 23 (PTI) Drug firm Zydus Cadila on Friday said it has received approval from the US health regulator to market Albuterol tablets, used to treat shortness of breath caused by breathing problems like asthma. The company has received final approval from the US Food and Drug Administration (USFDA) to market its product, which is a generic version of Proventil tablets, Zydus Cadila said in a statement.
Albuterol is a bronchodilator that can help open up the airways in the lungs to make it easier to breathe. The medication is used to treat and to prevent bronchospasm.
The drug firm said the product could be manufactured at the group”s formula manufacturing center at SEZ, Ahmedabad.
Zydus Cadila now has 310 approvals and thus far filed over 390 abbreviated new drug applications (ANDAs) since the initiation of the filing process in 2003-04. PTI MSS BAL BAL